Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers

Scott R. Penzak, Yuen Yi Hon, Walter D. Lawhorn, Kara L. Shirley, Vicky Spratlin, Michael W. Jann

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

HIV infection and psychotic illnesses frequently coexist. The atypical antipsychotic olanzapine is metabolized primarily by CYP1A2 and glucuronosyl transferases, both of which are induced by the HIV protease inhibitor ritonavir. The purpose of this study was to determine the effect of ritonavir on the pharmacokinetics of a single dose of olanzapine. Fourteen healthy volunteers (13 men; age range, 20-28 years) participated in this open-label study. Subjects received olanzapine 10 mg and blood samples were collected over a 120-hour post-dose period. Two weeks later, subjects took ritonavir 300 mg twice daily for 3 days, 400 mg twice daily for 4 days, and 500 mg twice daily for 4 days. The next morning, after 11 days of ritonavir, olanzapine 10 mg was administered and blood sampling was repeated. Plasma samples were analyzed for olanzapine with HPLC. We compared olanzapine non-compartmental pharmacokinetic parameter values before and after ritonavir with a paired Student t test. Ritonavir reduced the area under the plasma concentration-time curve of olanzapine from 501 ng · hr/mL (443-582) to 235 ng · hr/mL (197-294) (p < 0.001), the half-life from 32 hours (28-36) to 16 hours (14-18) (p = 0.00001), and the peak concentration from 15 ng/mL (13-19) to 9 ng/mL (8-12) (p = 0.002). Olanzapine oral clearance increased from 20 L/hr (18-23) to 43 L/hr (38-51) (p < 0.001) after ritonavir. Ritonavir significantly reduced the systemic exposure of olanzapine in volunteers. Patients receiving this combination may ultimately require higher olanzapine doses to achieve desired therapeutic effects.

Original languageEnglish (US)
Pages (from-to)366-370
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume22
Issue number4
DOIs
StatePublished - Aug 5 2002

Fingerprint

olanzapine
Ritonavir
Healthy Volunteers
Pharmacokinetics
HIV Protease Inhibitors
Cytochrome P-450 CYP1A2
Therapeutic Uses

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Penzak, S. R., Hon, Y. Y., Lawhorn, W. D., Shirley, K. L., Spratlin, V., & Jann, M. W. (2002). Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. Journal of Clinical Psychopharmacology, 22(4), 366-370. https://doi.org/10.1097/00004714-200208000-00006

Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. / Penzak, Scott R.; Hon, Yuen Yi; Lawhorn, Walter D.; Shirley, Kara L.; Spratlin, Vicky; Jann, Michael W.

In: Journal of Clinical Psychopharmacology, Vol. 22, No. 4, 05.08.2002, p. 366-370.

Research output: Contribution to journalArticle

Penzak, SR, Hon, YY, Lawhorn, WD, Shirley, KL, Spratlin, V & Jann, MW 2002, 'Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers', Journal of Clinical Psychopharmacology, vol. 22, no. 4, pp. 366-370. https://doi.org/10.1097/00004714-200208000-00006
Penzak, Scott R. ; Hon, Yuen Yi ; Lawhorn, Walter D. ; Shirley, Kara L. ; Spratlin, Vicky ; Jann, Michael W. / Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. In: Journal of Clinical Psychopharmacology. 2002 ; Vol. 22, No. 4. pp. 366-370.
@article{e73c850194374fe48e1095237158eaa4,
title = "Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers",
abstract = "HIV infection and psychotic illnesses frequently coexist. The atypical antipsychotic olanzapine is metabolized primarily by CYP1A2 and glucuronosyl transferases, both of which are induced by the HIV protease inhibitor ritonavir. The purpose of this study was to determine the effect of ritonavir on the pharmacokinetics of a single dose of olanzapine. Fourteen healthy volunteers (13 men; age range, 20-28 years) participated in this open-label study. Subjects received olanzapine 10 mg and blood samples were collected over a 120-hour post-dose period. Two weeks later, subjects took ritonavir 300 mg twice daily for 3 days, 400 mg twice daily for 4 days, and 500 mg twice daily for 4 days. The next morning, after 11 days of ritonavir, olanzapine 10 mg was administered and blood sampling was repeated. Plasma samples were analyzed for olanzapine with HPLC. We compared olanzapine non-compartmental pharmacokinetic parameter values before and after ritonavir with a paired Student t test. Ritonavir reduced the area under the plasma concentration-time curve of olanzapine from 501 ng · hr/mL (443-582) to 235 ng · hr/mL (197-294) (p < 0.001), the half-life from 32 hours (28-36) to 16 hours (14-18) (p = 0.00001), and the peak concentration from 15 ng/mL (13-19) to 9 ng/mL (8-12) (p = 0.002). Olanzapine oral clearance increased from 20 L/hr (18-23) to 43 L/hr (38-51) (p < 0.001) after ritonavir. Ritonavir significantly reduced the systemic exposure of olanzapine in volunteers. Patients receiving this combination may ultimately require higher olanzapine doses to achieve desired therapeutic effects.",
author = "Penzak, {Scott R.} and Hon, {Yuen Yi} and Lawhorn, {Walter D.} and Shirley, {Kara L.} and Vicky Spratlin and Jann, {Michael W.}",
year = "2002",
month = "8",
day = "5",
doi = "10.1097/00004714-200208000-00006",
language = "English (US)",
volume = "22",
pages = "366--370",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers

AU - Penzak, Scott R.

AU - Hon, Yuen Yi

AU - Lawhorn, Walter D.

AU - Shirley, Kara L.

AU - Spratlin, Vicky

AU - Jann, Michael W.

PY - 2002/8/5

Y1 - 2002/8/5

N2 - HIV infection and psychotic illnesses frequently coexist. The atypical antipsychotic olanzapine is metabolized primarily by CYP1A2 and glucuronosyl transferases, both of which are induced by the HIV protease inhibitor ritonavir. The purpose of this study was to determine the effect of ritonavir on the pharmacokinetics of a single dose of olanzapine. Fourteen healthy volunteers (13 men; age range, 20-28 years) participated in this open-label study. Subjects received olanzapine 10 mg and blood samples were collected over a 120-hour post-dose period. Two weeks later, subjects took ritonavir 300 mg twice daily for 3 days, 400 mg twice daily for 4 days, and 500 mg twice daily for 4 days. The next morning, after 11 days of ritonavir, olanzapine 10 mg was administered and blood sampling was repeated. Plasma samples were analyzed for olanzapine with HPLC. We compared olanzapine non-compartmental pharmacokinetic parameter values before and after ritonavir with a paired Student t test. Ritonavir reduced the area under the plasma concentration-time curve of olanzapine from 501 ng · hr/mL (443-582) to 235 ng · hr/mL (197-294) (p < 0.001), the half-life from 32 hours (28-36) to 16 hours (14-18) (p = 0.00001), and the peak concentration from 15 ng/mL (13-19) to 9 ng/mL (8-12) (p = 0.002). Olanzapine oral clearance increased from 20 L/hr (18-23) to 43 L/hr (38-51) (p < 0.001) after ritonavir. Ritonavir significantly reduced the systemic exposure of olanzapine in volunteers. Patients receiving this combination may ultimately require higher olanzapine doses to achieve desired therapeutic effects.

AB - HIV infection and psychotic illnesses frequently coexist. The atypical antipsychotic olanzapine is metabolized primarily by CYP1A2 and glucuronosyl transferases, both of which are induced by the HIV protease inhibitor ritonavir. The purpose of this study was to determine the effect of ritonavir on the pharmacokinetics of a single dose of olanzapine. Fourteen healthy volunteers (13 men; age range, 20-28 years) participated in this open-label study. Subjects received olanzapine 10 mg and blood samples were collected over a 120-hour post-dose period. Two weeks later, subjects took ritonavir 300 mg twice daily for 3 days, 400 mg twice daily for 4 days, and 500 mg twice daily for 4 days. The next morning, after 11 days of ritonavir, olanzapine 10 mg was administered and blood sampling was repeated. Plasma samples were analyzed for olanzapine with HPLC. We compared olanzapine non-compartmental pharmacokinetic parameter values before and after ritonavir with a paired Student t test. Ritonavir reduced the area under the plasma concentration-time curve of olanzapine from 501 ng · hr/mL (443-582) to 235 ng · hr/mL (197-294) (p < 0.001), the half-life from 32 hours (28-36) to 16 hours (14-18) (p = 0.00001), and the peak concentration from 15 ng/mL (13-19) to 9 ng/mL (8-12) (p = 0.002). Olanzapine oral clearance increased from 20 L/hr (18-23) to 43 L/hr (38-51) (p < 0.001) after ritonavir. Ritonavir significantly reduced the systemic exposure of olanzapine in volunteers. Patients receiving this combination may ultimately require higher olanzapine doses to achieve desired therapeutic effects.

UR - http://www.scopus.com/inward/record.url?scp=0036325312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036325312&partnerID=8YFLogxK

U2 - 10.1097/00004714-200208000-00006

DO - 10.1097/00004714-200208000-00006

M3 - Article

VL - 22

SP - 366

EP - 370

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 4

ER -